
    
      This is a prospective descriptive non-randomized clinical study to examine quality of life
      outcomes and use of pain and anti-emetic therapy for patients receiving HPN support. The
      EORTC QLQ-C30 will be used to evaluate quality of life. All subjects will be monitored
      monthly throughout the course of treatment for a minimum of 3 months and a maximum of 1 year.
    
  